# A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

> **NCT05723562** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 154 (actual)

## Conditions studied

- Neoplasms, Rectal

## Interventions

- **BIOLOGICAL:** Dostarlimab

## Key facts

- **NCT ID:** NCT05723562
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-03
- **Primary completion:** 2026-11-02
- **Final completion:** 2029-10-11
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05723562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05723562, "A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05723562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*